Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchBemnifosbuvirBemnifosbuvir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Bemnifosbuvir for COVID-19
3 studies from 35 scientists
359 patients in 3 countries
Statistically significant lower risk for hospitalization.
2 studies from 2 independent teams in 2 countries show statistically significant improvements.
COVID-19 Bemnifosbuvir studies. Feb 2024. c19early.org
0 0.5 1 1.5+ All studies 47% Mortality 86% Hospitalization 71% Recovery 12% Viral clearance 3% RCTs 47% Early 38% Late 86% Favorsbemnifosbuvir Favorscontrol
Feb 20
Covid Analysis Bemnifosbuvir for COVID-19: real-time meta analysis of 3 studies
Statistically significant lower risk is seen for hospitalization. 2 studies from 2 independent teams in 2 countries show statistically significant improvements. Meta analysis using the most serious outcome reported shows 47% [-57R..
Jan 8
Zhou et al., medRxiv, doi:10.1101/2024.01.03.24300783 Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19
Phase 1 study showing effective lung delivery and safety of the oral COVID-19 antiviral candidate bemnifosbuvir (AT-527) at 550mg twice daily. Authors found AT-527 550mg BID achieved sustained antiviral drug levels in lung fluids that exc..
Nov 1
2023
Horga et al., Future Virology, doi:10.2217/fvl-2023-0115 Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)
71% lower hospitalization (p=0.05), 28% lower progression (p=0.49), 28% slower recovery, and 22% improved viral clearance (p=0.21). MORNINGSKY RCT which was terminated early after enrolling only 216 of 1,386 planned participants. The trial did not meet its primary endpoint, with the bemnifosbuvir group having longer time to symptom improvement than placebo. However, c..
Aug 17
2023
Boffito et al., Microbiology Spectrum, doi:10.1128/spectrum.00077-23 A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study)
3% improved viral clearance (p=0.14). RCT 100 mild/moderate COVID-19 patients showing no significant difference in nasopharyngeal viral load reduction between bemnifosbuvir (550mg or 1100mg twice daily for 5 days) and placebo groups.
Jun 23
2023
Horga et al., Future Virology, doi:10.2217/fvl-2023-0064 Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19
86% lower mortality (p=0.24), 2% improved recovery (p=1), and 9% improved viral clearance (p=0.8). Phase 2 RCT investigating bemnifosbuvir for the treatment of 81 high-risk COVID-19 patients hospitalized with moderate disease. The trial was terminated early due to difficulties with enrollment. There was no significant difference betwee..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit